Nplate® is a thrombopoietin receptor agonist indicated for the treatment of thrombocytopenia in adult patients with immune... Read More
*Among the 19% of Nplate® claims where patients had out-of-pocket (OOP) costs, most claims (72%) had an OOP cost of less than $400. Data based on Symphony Health Solutions claims data. 24,199 Nplate® claims were identified between 1/1/2019 - 12/31/2019 for all payors, including commercial and government.1
See How We Can Help Your Patients
Amgen Assist 360™ and Nplate® Navigator are here to offer the tools, information, and support for Amgen products that make a difference for you and your patients.
Amgen Assist 360™:
Introducing support, simplified
Amgen Reimbursement Specialists
- Connect with an Amgen Reimbursement Counselor or schedule a visit with a Field Reimbursement Specialist
- Find co-pay and reimbursement resources for patients with different kinds of insurance or no insurance at all
- Submit, store, and retrieve benefit verifications for all your patients currently on an Amgen product
To learn more, please visit www.AmgenAssist360.com.
The Amgen FIRST STEP™ Prepaid Mastercard® is issued by Comerica Bank pursuant to license by Mastercard® International Incorporated. No cash or ATM access. Mastercard® is a registered trademark of Mastercard® International Incorporated. This card can be used only to cover the co-payment for eligible prescriptions covered under the program at participating merchant locations where Debit Mastercard® is accepted.
The Amgen FIRST STEP™ program
Who it may help
- Eligible† commercially insured patients
The Amgen FIRST STEP™ program can help your eligible† commercially insured patients cover their out-of-pocket (OOP) prescription costs, including deductible, co-insurance, and co-payment.
- $0 OOP for first dose
- $5 OOP for subsequent doses, up to the brand benefit maximum
- No income eligibility requirement
See AmgenFirstStep.com for terms and conditions.
†Terms, conditions, and program maximums apply. This program is not open to patients receiving prescription reimbursement under any federal, state, or government-funded healthcare program. Not valid where prohibited by law.
Referrals to the Amgen Safety Net Foundation
- The Amgen Safety Net Foundation provides Amgen products at no cost to qualifying patients.
- Patients may qualify if they have no or limited drug coverage and meet income eligibility requirements.
- Patient must be a US resident to qualify.
Nplate® Navigator patient support program
Nplate® Navigator may help:
- Answer questions about immune thrombocytopenia (ITP) and Nplate® by allowing your patients to speak with a nurse*
- Provide information about finding resources that may be able to help your patients afford their medication
- Identify a list of local ITP specialists while patients are traveling or relocating domestically
- Keep patients informed with educational emails and direct mailings
*The Nplate® Navigator program and its nurses are not intended to provide medical advice, diagnose health problems, or take the place of speaking with a healthcare professional about a patient’s condition, treatment, or medication.Learn about patient access and reimbursement
Important Safety Information
Risk of Progression of Myelodysplastic Syndromes to Acute Myelogenous Leukemia
- In Nplate® (romiplostim) clinical trials of patients with myelodysplastic syndromes (MDS) and severe thrombocytopenia, progression from MDS to acute myelogenous leukemia (AML) has been observed.
- Nplate® is not indicated for the treatment of thrombocytopenia due to MDS or any cause of thrombocytopenia other than ITP.
- Thrombotic/thromboembolic complications may result from increases in platelet counts with Nplate® use. Portal vein thrombosis has been reported in patients with chronic liver disease receiving Nplate®.
- To minimize the risk for thrombotic/thromboembolic complications, do not use Nplate® in an attempt to normalize platelet counts. Follow the dose adjustment guidelines to achieve and maintain a platelet count of ≥ 50 x 109/L.
Loss of Response to Nplate®
- Hyporesponsiveness or failure to maintain a platelet response with Nplate® should prompt a search for causative factors, including neutralizing antibodies to Nplate®.
- To detect antibody formation, submit blood samples to Amgen (1‑800‑772‑6436). Amgen will assay these samples for antibodies to Nplate® and thrombopoietin (TPO).
- Discontinue Nplate® if the platelet count does not increase to a level sufficient to avoid clinically important bleeding after 4 weeks at the highest weekly dose of 10 mcg/kg.
- In the placebo-controlled trials of adult ITP patients, headache was the most commonly reported adverse drug reaction, occurring in 35% of patients receiving Nplate® and 32% of patients receiving placebo. Adverse drug reactions in adults with a ≥ 5% higher patient incidence in Nplate® versus placebo were Arthralgia (26%, 20%), Dizziness (17%, 0%), Insomnia (16%, 7%), Myalgia (14%, 2%), Pain in Extremity (13%, 5%), Abdominal Pain (11%, 0%), Shoulder Pain (8%, 0%), Dyspepsia (7%, 0%), and Paresthesia (6%, 0%).
- The safety profile of Nplate® was similar across patients, regardless of ITP duration. The following adverse reactions (at least 5% incidence and at least 5% more frequent with Nplate® compared with placebo or standard of care) occurred in Nplate® patients with ITP duration up to 12 months: bronchitis, sinusitis, vomiting, arthralgia, myalgia, headache, dizziness, diarrhea, upper respiratory tract infection, cough, nausea and oropharyngeal pain. The adverse reaction of thrombocytosis occurred with an incidence of 2% in adults with ITP duration up to 12 months.
- The most common adverse reactions experienced by ≥ 5% of patients receiving Nplate® with ≥ 5% higher incidence in the Nplate® arm across the two placebo-controlled trials were contusion (41%), upper respiratory tract infection (31%), oropharyngeal pain (25%), pyrexia (24%), diarrhea (20%), rash (15%), and upper abdominal pain (14%).
- In pediatric patients of age ≥ 1 year receiving Nplate® for ITP, adverse reactions with an incidence of ≥ 25% in the two randomized trials were: contusion (41%), upper respiratory tract infection (31%), and oropharyngeal pain (25%).
Nplate® administration may increase the risk for development or progression of reticulin fiber formation within the bone marrow. This formation may improve upon discontinuation of Nplate®. In a clinical trial, one patient with ITP and hemolytic anemia developed marrow fibrosis with collagen during Nplate® therapy.
Nplate® is a thrombopoietin receptor agonist indicated for the treatment of thrombocytopenia in adult patients with immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. Nplate® is indicated for the treatment of thrombocytopenia in pediatric patients 1 year of age and older with ITP for at least 6 months who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.
Nplate® is not indicated for the treatment of thrombocytopenia due to myelodysplastic syndrome (MDS) or any cause of thrombocytopenia other than ITP. Nplate® should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increase the risk for bleeding. Nplate® should not be used in an attempt to normalize platelet counts.
Reference: 1. Data on file, Amgen; Patient OOP; 2019.